EZI activators, or Enhancer of Zeste Inhibitor activators, are a class of chemical compounds that specifically interact with a family of proteins known as Polycomb-group (PcG) proteins. PcG proteins are involved in the regulation of gene expression through the modification of chromatin structure, which is the complex of DNA and protein found in the nucleus of eukaryotic cells. One of the key components of this protein family is the Enhancer of Zeste homolog 2 (EZH2), which acts as a methyltransferase, transferring methyl groups to histone proteins-the core components around which DNA is wound. This methylation is a critical process in the epigenetic regulation of genes, playing an essential role in the control of gene activation and repression. EZI activators are designed to modulate the activity of EZH2, thereby influencing the methylation status of histones and ultimately affecting the expression pattern of genes.
The molecular design of EZI activators is rooted in the understanding of the enzymatic mechanism of EZH2. By binding to the catalytic site or allosteric sites of EZH2, these activators can modulate the activity of the enzyme. The structure-activity relationship (SAR) of these molecules is an active area of research, focusing on optimizing the interactions between the EZI activators and EZH2 proteins to achieve desired modulation effects. These compounds are often characterized by their ability to influence the tri-methylation state of histone H3 on lysine 27 (H3K27me3), which is a hallmark of EZH2 enzymatic activity. Understanding the precise mechanism by which EZI activators exert their effect on EZH2 involves detailed studies of molecular biology, biochemistry, and structural biology to elucidate the interaction between these small molecules and their target protein at the atomic level.
Items 11 to 12 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. By inhibiting p38, it can change the balance of cellular signaling towards pathways that might activate EZI, as p38 MAPK can negatively regulate various signaling pathways. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is an inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to an increase in cytosolic calcium levels. Elevated calcium may activate calcium-dependent signaling pathways that indirectly enhance the activity of EZI. | ||||||